How India Exports Lisinopril to the World

In the United States, Lisinopril is approved for the treatment of hypertension and heart failure. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for Lisinopril, reflecting its status as a well-established generic medication. Recent approvals include those granted in January 2026, underscoring ongoing interest and market activity. The regulatory pathway for Lisinopril involves the submission of an ANDA, demonstrating bioequivalence to the reference listed drug. Given that 25% of India's Lisinopril exports are directed to the U.S., the presence of 221 active Indian exporters highlights the competitive landscape and the importance of stringent compliance with FDA regulations to ensure market access.

In the European Union, Lisinopril is authorized for marketing through national procedures, with oversight by the European Medicines Agency (EMA) ensuring compliance with EU Good Manufacturing Practice (GMP) standards. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates Lisinopril, requiring adherence to UK GMP requirements. The significant export volumes to the Netherlands (42.6%) and the UK (3.8%) necessitate that Indian manufacturers maintain rigorous quality standards and comply with the respective regulatory frameworks to facilitate smooth market entry and sustained presence.

Lisinopril is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, affirming its critical role in treating priority health conditions globally. This inclusion underscores the medication's efficacy, safety, and cost-effectiveness. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to ensure product quality and facilitate international trade.

In India, Lisinopril is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has set a ceiling price for Lisinopril, with the latest revision in March 2025, to ensure affordability and accessibility. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and facilitating international shipments.

The primary patents for Lisinopril have expired, leading to a robust generic market with significant competition. This competitive environment is reflected in the substantial number of active Indian exporters (221) and the diverse global market reach, encompassing 94 destination countries.

In January 2026, the NPPA revised the ceiling price for Lisinopril, reflecting efforts to balance affordability with industry sustainability. In February 2026, the CDSCO issued updated guidelines for the export of pharmaceutical products, emphasizing the need for stringent quality control measures. In March 2026, the WHO released the 24th edition of the Model List of Essential Medicines, reaffirming Lisinopril's inclusion and highlighting its continued importance in global health. These developments underscore the dynamic regulatory landscape and the necessity for manufacturers to stay informed and compliant to maintain market access and competitiveness.

India's pharmaceutical industry, including the production of Lisinopril, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) sourced from China. This dependency is significant, with approximately 60–70% of KSMs and intermediates imported from China. Such reliance exposes the supply chain to vulnerabilities, as disruptions in China's production or export activities can directly impact the availability and cost of these essential materials.

Recent geopolitical tensions have exacerbated these risks. For instance, in June 2025, escalating conflicts led to the closure of the Strait of Hormuz, a critical passage for global trade. This event disrupted the supply of raw materials, including those necessary for pharmaceutical manufacturing, highlighting the fragility of the supply chain. (pharmasource.global) Such incidents underscore the need for diversification in sourcing strategies to mitigate potential disruptions.

The export data for Lisinopril from India reveals a high supplier concentration, with the top five exporters accounting for 78.2% of the total export value. Notably, MYLAN LABORATORIES LIMITED alone contributes 42.3% of this share. This concentration poses a significant single-source risk; any operational or regulatory issues affecting these key suppliers could lead to substantial disruptions in the supply chain.

To address such vulnerabilities, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic production of critical APIs and KSMs. By November 2024, two greenfield plants were inaugurated under this scheme, focusing on the production of essential molecules used in common antibiotics. While these initiatives are steps toward reducing import dependence, the effectiveness of the PLI scheme in diversifying the supplier base for Lisinopril remains to be fully realized.

Geopolitical tensions have led to significant disruptions in global shipping routes, notably the Red Sea and the Strait of Hormuz. In March 2026, conflicts in these regions resulted in the effective shutdown of the Strait of Hormuz, a vital conduit for global trade. This closure disrupted the supply of raw materials essential for pharmaceutical manufacturing, including those used in Lisinopril production.

Additionally, the Red Sea conflict has posed risks to the supply of key pharmaceutical ingredients and chemicals, affecting shipments from Asia to the US and Europe. These disruptions have led to increased shipping costs and delays, further straining the pharmaceutical supply chain. (pharmasource.global) Such geopolitical instabilities underscore the importance of developing resilient supply chains to withstand external shocks.

• Diversify Sourcing Strategies: Identify and establish relationships with alternative suppliers for APIs and KSMs beyond China to reduce dependency and mitigate risks associated with geopolitical tensions.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for critical APIs and KSMs, leveraging government initiatives like the PLI scheme to build a more self-reliant supply chain.

• Strengthen Supplier Relationships: Develop strategic partnerships with multiple suppliers to distribute risk and ensure a steady supply of essential materials.

• Implement Robust Risk Management Frameworks: Establish comprehensive risk assessment and management protocols to proactively identify potential disruptions and develop contingency plans.

• Monitor Geopolitical Developments: Stay informed about global political and economic events that could impact supply chains, enabling timely responses to emerging risks.

RISK_LEVEL: HIGH